• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis.

作者信息

Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon H J, Haim M, Johnell O, Jönsson B, Kanis J A, Tsouderos Y, Reginster J-Y

机构信息

Centre for Health Economics, Stockholm School of Economics, Sweden.

出版信息

Osteoporos Int. 2002 Nov;13(11):841-57. doi: 10.1007/s001980200117.

DOI:10.1007/s001980200117
PMID:12415431
Abstract
摘要

相似文献

1
Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis.评估骨质疏松症治疗和预防成本效益的模型
Osteoporos Int. 2002 Nov;13(11):841-57. doi: 10.1007/s001980200117.
2
[Cost-effectiveness on osteoporosis of HRT].[激素替代疗法治疗骨质疏松症的成本效益]
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:615-21.
3
A review of economic evaluation in osteoporosis.骨质疏松症的经济评估综述
Arthritis Care Res. 1999 Dec;12(6):425-34. doi: 10.1002/1529-0131(199912)12:6<425::aid-art11>3.0.co;2-a.
4
[Prevention of osteoporosis using estrogen and gestagens].[使用雌激素和孕激素预防骨质疏松症]
Gynakologe. 1992 Feb;25(1):31-5.
5
Epidemiologic and economic considerations of osteoporosis.
J Fla Med Assoc. 1996 Oct;83(8):548-51.
6
Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
Med Decis Making. 2006 Nov-Dec;26(6):633-5; author reply 636-7. doi: 10.1177/0272989X06295363.
7
Early prevention vs late treatment for osteoporosis.骨质疏松症的早期预防与晚期治疗
Arch Intern Med. 1997;157(22):2545-6.
8
HRT: an analysis of benefits, risks and costs.激素替代疗法：益处、风险及成本分析
Br Med Bull. 1992 Apr;48(2):368-400. doi: 10.1093/oxfordjournals.bmb.a072552.
9
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions.基于模型的绝经后骨质疏松症干预措施经济评估面临的挑战。
Osteoporos Int. 2001;12(10):849-57. doi: 10.1007/s001980170036.
10
[Grave deficiencies in the diagnosis and therapy of osteoporosis. Expensive fracture landing].
MMW Fortschr Med. 2002 Feb 14;144(7):20-1.

引用本文的文献

1
Does Simultaneous Computed Tomography and Quantitative Computed Tomography Show Better Prescription Rate than Dual-energy X-ray Absorptiometry for Osteoporotic Hip Fracture?对于骨质疏松性髋部骨折，同步计算机断层扫描和定量计算机断层扫描的处方率是否比双能X线吸收法更高？
Hip Pelvis. 2018 Dec;30(4):233-240. doi: 10.5371/hp.2018.30.4.233. Epub 2018 Dec 6.
2
A brief history of FRAX.FRAX 的简史。
Arch Osteoporos. 2018 Oct 31;13(1):118. doi: 10.1007/s11657-018-0510-0.
3
A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.
绝经后骨质疏松症药物成本效益分析的系统评价
Pharmacoeconomics. 2015 Mar;33(3):205-24. doi: 10.1007/s40273-014-0231-1.
4
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures.用于预防骨质疏松性骨折的成本效益分析模型的系统评价。
Osteoporos Int. 2014 Jan;25(1):51-60. doi: 10.1007/s00198-013-2551-y. Epub 2013 Oct 24.
5
Health technology assessment in osteoporosis.骨质疏松症的卫生技术评估。
Calcif Tissue Int. 2013 Jul;93(1):1-14. doi: 10.1007/s00223-013-9724-8. Epub 2013 Mar 21.
6
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.伊班膦酸钠预防炎性肠病相关性骨质疏松症骨折的成本效益：使用马尔可夫模型的成本效用分析
Pharmacoeconomics. 2008;26(4):311-28. doi: 10.2165/00019053-200826040-00004.
7
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.欧洲绝经后女性骨质疏松症诊断与管理指南。
Osteoporos Int. 2008 Apr;19(4):399-428. doi: 10.1007/s00198-008-0560-z. Epub 2008 Feb 12.
8
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.瑞典高危骨质疏松、高血压和高脂血症女性患者治疗的成本效益分析
Osteoporos Int. 2008 Jun;19(6):819-27. doi: 10.1007/s00198-007-0511-0.
9
Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures.预防骨质疏松相关骨折的药物治疗的成本效益建模研究
Curr Rheumatol Rep. 2007 Apr;9(1):50-6. doi: 10.1007/s11926-007-0022-1.
10
Non-compliance: the Achilles' heel of anti-fracture efficacy.不依从性：抗骨折疗效的致命弱点。
Osteoporos Int. 2007 Jun;18(6):711-9. doi: 10.1007/s00198-006-0294-8. Epub 2007 Jan 24.